Sanofi (SAN.PA)
| Previous close | 87.70 |
| Open | 87.68 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 87.63 - 92.56 |
| 52-week range | 80.60 - 104.90 |
| Volume | |
| Avg. volume | 1,365,420 |
| Market cap | 115.786B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 21.29 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.76 (4.29%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- Insider Monkey
20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
- Investor's Business Daily
AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.
- Reuters
UPDATE 2-Sanofi profit slips on generic competition and currency effects
Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.
